相关临床试验
811
71 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1908
进行中（未招募）
29
3.6%
已完成
485
59.8%
Enrolling By Invitation
4
0.5%
尚未招募
38
4.7%
招募中
132
16.3%
暂停
2
0.3%
终止
66
8.1%
Unknown
1
0.1%
撤回
54
6.7%
暂无批准数据
- A fully remote, three-arm randomized controlled trial across 13 countries (n=825) found the eMPower digital program significantly reduced anxiety and depression symptoms compared with usual care at 12 weeks. - The human-supported arm improved HADS total score by 2.9 points (95% CI 2.0–3.8; p<0.001), with the self-directed arm showing a comparable 2.6-point improvement (95% CI 1.8–3.5; p<0.001). - Exploratory analyses found no significant difference between self-directed and human-supported delivery, suggesting a scalable "digital first" model may be feasible for broad implementation. - Fatigue (MFIS) and health-related quality of life also improved significantly, with no intervention-related adverse events reported across any arm.
- Xanadu Quantum Technologies and the University of Alberta have formed a strategic research partnership to develop quantum algorithms for designing photosensitizers used in photodynamic cancer therapy. - The collaboration pairs Xanadu's fault-tolerant algorithm pipeline and PennyLane software stack with Professor Alex Brown's expertise in computational photodynamics modeling. - The project targets excited-state dynamics, wavelength sensitivity, and singlet oxygen generation efficiency, which classical density functional theory and quantum chemistry methods struggle to resolve. - The partnership aims to position early fault-tolerant quantum computing as a competitive method for accelerating photodynamic drug discovery.
- A University of Alberta study analyzing 971 TikTok videos found anti-sunscreen content, though only 6% of total posts, garners disproportionately high audience engagement compared to pro-sunscreen messaging. - Researchers identified that only 6% of sunscreen-related TikTok content mentions cancer risk reduction, with the majority instead focusing on beauty and anti-aging benefits. - A separate 2023 study in Cancer Epidemiology, Biomarkers & Prevention found the "sunscreen paradox" — where sunscreen users may experience increased skin cancer risk due to a false sense of security leading to prolonged UV exposure, not due to sunscreen itself. - Experts recommend dermatologists and brands adopt shorter, clearer messaging on social media that directly addresses sunscreen's role in skin cancer prevention while acknowledging patient concerns.
- The Canadian government announced an additional $50 million investment through the Regional Innovation Ecosystems program to support the Canadian Critical Drug Initiative and strengthen domestic pharmaceutical manufacturing capacity. - Applied Pharmaceutical Innovation will partner with the University of Alberta to construct the Critical Medicines Production Centre, enabling end-to-end large-scale manufacturing of various pharmaceutical products in Canada. - The initiative aims to address global supply chain vulnerabilities, reduce drug shortages, and enhance Canada's biodefence capabilities while creating over 350 high-quality jobs. - The investment is expected to support the growth of at least 60 early-stage life sciences and biomanufacturing companies and train 175 skilled workers in the Edmonton area.
- University of Alberta researchers are conducting clinical trials across seven Canadian sites for a precision diet tool that analyzes gut microbiome to optimize nutrition for inflammatory bowel disease patients. - The AI-powered system cultures gut microbes with different carbohydrates from stool samples and creates personalized dietary recommendations, showing increased remission rates in IBD patients within weeks to months. - The $10-million Weston Family Foundation-funded research has demonstrated benefits beyond IBD, with healthy participants reporting improved cardiovascular health and overall wellbeing. - The precision diet approach focuses on optimizing nondigestible carbohydrates and emphasizes whole food consumption, with clinical availability expected within three years.
- Onco-Innovations has entered into a research agreement with the University of Alberta and Cross Cancer Institute to expand preclinical studies of its PNKP inhibitor technology for hard-to-treat cancers, beginning with glioblastoma multiforme. - The study will focus on evaluating the therapeutic potential of the company's second-generation nanoparticle formulation of PNKP inhibitors against GBM, which accounts for approximately 50% of all primary malignant brain tumors and affects over 200,000 individuals worldwide annually. - Research will be led by Dr. Michael Weinfeld, the original discoverer of the PNKP inhibitor technology, with the preclinical program scheduled to begin in the third quarter of 2025. - Key investigation areas will include pharmacological characteristics, DNA damage enhancement in tumor models, effects on normal brain tissue, and potential combination strategies with standard-of-care therapies.
- A groundbreaking 17-year international clinical trial involving 889 colon cancer patients shows that structured exercise programs reduce cancer recurrence risk by 28% and death risk by 37%. - The CO.21 Challenge study, published in the New England Journal of Medicine, is the first clinical trial designed specifically to test whether exercise can improve cancer survival outcomes. - Researchers emphasize that exercise should now be considered a standard treatment for colon cancer rather than just a quality-of-life intervention, requiring integration into healthcare systems. - The study involved patients with Stage 3 or high-risk Stage 2 colon cancer who completed surgery and chemotherapy, with participants following a 3-year structured exercise program of 2.5 hours weekly moderate-intensity activity.
- Onco-Innovations has partnered with Dalton Pharma Services to begin manufacturing 50 grams of their proprietary PNKP inhibitor A83B4C63 for preclinical testing. - The nanoparticle-formulated inhibitor previously demonstrated significant survival benefits in colorectal cancer models, extending median survival from 23 to 60 days in PTEN-deficient mice. - This manufacturing milestone represents a critical transition from early research to production scale-up, supporting the company's planned IND submission to the FDA this year.
- University of Alberta researchers have developed Zelenirstat, an innovative oral cancer medication that works by preventing cancer cell spread and starving tumors. - The FDA has granted fast-track designation to Zelenirstat, potentially accelerating its development and review process for cancer treatment. - This breakthrough represents a significant advance in cancer therapy, offering patients a convenient at-home treatment option compared to traditional cancer therapies.
